Substituted pyrazolone compounds and methods of use

1. A compound of Formula (I):

or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein:

Q is D, —N(R c )C(═O)NR a R b , —N(R c )C(═O)R d , —C(═O)NR a R b , —N(R c )S(═O)NR a R b , —N(R c )S(═O)R a , —N(R c )S(═O) 2 NR a R b or —N(R c )S(═O) 2 R a ;

W is CR 7 or N;

each of X, Y and Z is independently H, D, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, —(C 1 -C 4 )alkylene-(C 3 -C 8 )cycloalkyl, (C 3 -C 7 )heterocyclyl, —(C 1 -C 4 )alkylene-(C 3 -C 7 )heterocyclyl, (C 6 -C 10 )aryl, 5-10 membered heteroaryl comprising 1, 2, 3 or 4 heteroatoms independently selected from O, S and N, —(C 1 -C 4 )alkylene-(C 6 -C 10 )aryl or —(C 1 -C 4 )alkylene-(5-10 membered heteroaryl), wherein each of the (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, —(C 1 -C 4 )alkylene-(C 3 -C 8 )cycloalkyl, (C 3 -C 7 )heterocyclyl, —(C 1 -C 4 )alkylene-(C 3 -C 7 )heterocyclyl, (C 6 -C 10 )aryl, 5-10 membered heteroaryl, —(C 1 -C 4 )alkylene-(C 6 -C 10 )aryl and —(C 1 -C 4 )alkylene-(5-10 membered heteroaryl) is unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from D, F, Cl, Br, CN, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, OR a , NR a R b , —(C 1 -C 4 )alkylene-OR a and —(C 1 -C 4 )alkylene-NR a R b ;

each of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 is independently H, D, F, Cl, Br, CN, N 3 , OR a , (C 1 -C 6 )alkyl, (C 1 -C 6 )haloalkyl, (C 2 -C 6 )alkenyl or (C 2 -C 6 )alkynyl;

each of R a , R b and R c is independently H, (C 1 -C 6 )aliphatic, (C 1 -C 6 )haloalkyl, (C 3 -C 6 )cycloalkyl, —(C 1 -C 4 )alkylene-(C 3 -C 6 )cycloalkyl, (C 3 -C 6 )heterocyclyl, —(C 1 -C 4 )alkylene-(C 3 -C 6 )heterocyclyl, (C 6 -C 10 )aryl, 5-10 membered heteroaryl comprising 1, 2, 3 or 4 heteroatoms independently selected from O, S and N, —(C 1 -C 4 )alkylene-(C 6 -C 10 )aryl or —(C 1 -C 4 )alkylene-(5-10 membered heteroaryl), wherein each of the (C 1 -C 6 )aliphatic, (C 1 -C 6 )haloalkyl, (C 3 -C 6 )cycloalkyl, —(C 1 -C 4 )alkylene-(C 3 -C 6 )cycloalkyl, (C 3 -C 6 )heterocyclyl, —(C 1 -C 4 )alkylene-(C 3 -C 6 )heterocyclyl, (C 6 -C 10 )aryl, 5-10 membered heteroaryl, —(C 1 -C 4 )alkylene-(C 6 -C 10 )aryl and —(C 1 -C 4 )alkylene-(5-10 membered heteroaryl) is unsubstituted or optionally substituted with 1, 2, 3 or 4 substitutents independently selected from D, F, Cl, CN, N 3 , OH, NH 2 , (C 1 -C 6 )haloalkyl, (C 1 -C 6 )alkoxy and (C 1 -C 6 )alkylamino; and

R d is D, (C 3 -C 8 )cycloalkyl, —(C 1 -C 4 )alkylene-(C 6 -C 10 )aryl, 5-10 membered heteroaryl comprising 1, 2, 3 or 4 heteroatoms independently selected from O, S and N or —(C 1 -C 4 )alkylene-(5-10 membered heteroaryl), wherein each of the (C 3 -C 8 )cycloalkyl, —(C 1 -C 4 )alkylene-(C 6 -C 10 )aryl, 5-10 membered heteroaryl and —(C 1 -C 4 )alkylene-(5-10 membered heteroaryl) is unsubstituted or optionally substituted with 1, 2, 3 or 4 substitutents independently selected from D, F, Cl, Br, CN, OR a , NR a R b , (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, —(C 1 -C 4 )alkylene-OR a and —(C 1 -C 4 )alkylene-NR a R b .

2. The compound according to claim 1 , wherein each of R a , R b and R o is independently H, (C 1 -C 6 )aliphatic, (C 1 -C 6 )haloalkyl, (C 3 -C 6 )cycloalkyl, (C 3 -C 6 )heterocyclyl, —(C 1 -C 4 )alkylene-(C 3 -C 6 )heterocyclyl, (C 6 -C 10 )aryl, 5-10 membered heteroaryl comprising 1, 2, 3 or 4 heteroatoms independently selected from O, S and N, —(C 1 -C 4 )alkylene-(C 6 -C 10 )aryl or —(C 1 -C 4 )alkylene-(5-10 membered heteroaryl), wherein each of the (C 1 -C 6 )aliphatic, (C 1 -C 6 )haloalkyl, (C 3 -C 6 )cycloalkyl, (C 3 -C 6 )heterocyclyl, —(C 1 -C 4 )alkylene-(C 3 -C 6 )heterocyclyl, (C 6 -C 10 )aryl, 5-10 membered heteroaryl, —(C 1 -C 4 )alkylene-(C 6 -C 10 )aryl and —(C 1 -C 4 )alkylene-(5-10 membered heteroaryl) is unsubstituted or optionally substituted with 1, 2, 3 or 4 substitutents independently selected from D, F, Cl, CN, N 3 , OH, NH 2 , (C 1 -C 6 )haloalkyl, (C 1 -C 6 )alkoxy and (C 1 -C 6 )alkylamino; and

R d is D, (C 3 -C 8 )cycloalkyl, —(C 1 -C 4 )alkylene-(C 6 -C 10 )aryl, 5-10 membered heteroaryl comprising 1, 2, 3 or 4 heteroatoms independently selected from O, S and N or —(C 1 -C 4 )alkylene-(5-10 membered heteroaryl), wherein each of the (C 3 -C 8 )cycloalkyl, —(C 1 -C 4 )alkylene-(C 6 -C 10 )aryl, 5-10 membered heteroaryl and —(C 1 -C 4 )alkylene-(5-10 membered heteroaryl) is unsubstituted or optionally substituted with 1, 2, 3 or 4 substitutents independently selected from D, F, Cl, Br, CN, OR a , NR a R b , (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, —(C 1 -C 4 )alkylene-OR a and —(C 1 -C 4 )alkylene-NR a R b .

3. The compound according to claim 1 , wherein Q is —N(R c )C(═O)NR a R b , —N(R c )C(═O)R d or —C(═O)NR a R b .

4. The compound according to claim 1 , wherein each of X, Y and Z is independently (C 1 -C 4 )alkyl, (C 3 -C 6 )cycloalkyl, —(C 1 -C 2 )alkylene-(C 3 -C 6 )cycloalkyl, (C 3 -C 6 )heterocyclyl, —(C 1 -C 2 )alkylene-(C 3 -C 6 )heterocyclyl, phenyl, 5-10 membered heteroaryl comprising 1, 2, 3 or 4 heteroatoms independently selected from O, S and N, —(C 1 -C 2 )alkylene-phenyl or —(C 1 -C 2 )alkylene-(5-10 membered heteroaryl), wherein each of the (C 1 -C 4 )alkyl, (C 3 -C 6 )cycloalkyl, —(C 1 -C 2 )alkylene-(C 3 -C 6 )cycloalkyl, (C 3 -C 6 )heterocyclyl, —(C 1 -C 2 )alkylene-(C 3 -C 6 )heterocyclyl, phenyl, 5-10 membered heteroaryl, —(C 1 -C 2 )alkylene-phenyl and —(C 1 -C 2 )alkylene-(5-10 membered heteroaryl) is unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from D, F, Cl, CN, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, OR a , NR a R b , —(C 1 -C 2 )alkylene-OR a and —(C 1 -C 2 )alkylene-NR a R b .

5. The compound according to claim 1 , wherein each of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 is independently H, D, F or Cl.

6. The compound according to claim 1 , wherein each of R a , R b and R c is independently H, (C 1 -C 4 )alkyl, (C 1 -C 4 )haloalkyl, (C 3 -C 6 )cycloalkyl, —(C 1 -C 2 )alkylene-(C 3 -C 6 )cycloalkyl, (C 3 -C 6 )heterocyclyl or —(C 1 -C 2 )alkylene-(C 3 -C 6 )heterocyclyl, wherein each of the (C 1 -C 4 )alkyl, (C 1 -C 4 )haloalkyl, (C 3 -C 6 )cycloalkyl, —(C 1 -C 2 )alkylene-(C 3 -C 6 )cycloalkyl, (C 3 -C 6 )heterocyclyl and —(C 1 -C 2 )alkylene-(C 3 -C 6 )heterocyclyl is unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from D, F, Cl, CN, N 3 , OH, NH 2 , (C 1 -C 3 )haloalkyl, (C 1 -C 3 )alkoxy and (C 1 -C 3 )alkyl amino.

7. The compound according to claim 1 , wherein R d is (C 3 -C 6 )cycloalkyl, wherein the (C 3 -C 6 )cycloalkyl is unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from D, F, CN, OR a , NR a R b , (C 1 -C 3 )alkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, —(C 1 -C 2 )alkylene-OR a and —(C 1 -C 2 )alkylene-NR a R b .

8. The compound according to claim 1 , wherein each of X, Y and Z is independently H, D, CH 3 , methyl group substituted with 1, 2 or 3 deuterium atoms, ethyl, propyl, isopropyl, phenyl or phenyl group substituted with 1, 2, 3, 4 or 5 substituents independently selected from D, F and Cl.

9. The compound according to claim 1 , wherein Q is:

10. The compound of claim 1 having Formula (II):

wherein:

Q is —N(R c )C(═O)NR a R b , —N(R c )C(═O)R d , —N(R c )S(═O)NR a R b , —N(R c )S(═O)R a , —N(R c )S(═O) 2 NR a R b , —N(R c )S(═O) 2 R a or —C(═O)NR a R b ;

each of X, Y and Z is independently H, D, (C 1 -C 6 )alkyl, (C 3 -C 7 )cycloalkyl, (C 3 -C 7 )heterocyclyl, (C 6 -C 10 )aryl, 5-10 membered heteroaryl comprising 1, 2, 3 or 4 heteroatoms independently selected from O, S and N, —(C 1 -C 4 )alkylene-(C 3 -C 8 )cycloalkyl, —(C 1 -C 4 )alkylene-(C 3 -C 7 )heterocyclyl, —(C 1 -C 4 )alkylene-(C 6 -C 10 )aryl or —(C 1 -C 4 )alkylene-(5-10 membered heteroaryl), wherein each of the (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C 3 -C 7 )heterocyclyl, (C 6 -C 10 )aryl, 5-10 membered heteroaryl, —(C 1 -C 4 )alkylene-(C 3 -C 8 )cycloalkyl, —(C 1 -C 4 )alkylene-(C 3 -C 7 )heterocyclyl, —(C 1 -C 4 )alkylene-(C 6 -C 10 )aryl and —(C 1 -C 4 )alkylene-(5-10 membered heteroaryl) is optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from D, F, Cl, Br, CN, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, OR a , NR a R b , —(C 1 -C 4 )alkylene-OR a and —(C 1 -C 4 )alkylene-NR a R b ;

each of R a , R b and R c is independently H, (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 3 -C 6 )heterocyclyl, (C 6 -C 10 )aryl, 5-10 membered heteroaryl comprising 1, 2, 3 or 4 heteroatoms independently selected from O, S and N, —(C 1 -C 4 )alkylene-(C 3 -C 6 )cycloalkyl, —(C 1 -C 4 )alkylene-(C 3 -C 6 )heterocyclyl, (C 1 -C 4 )alkylene-(C 6 -C 10 )aryl or —(C 1 -C 4 )alkylene-(5-10 membered heteroaryl), wherein each of the (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 3 -C 6 )heterocyclyl, (C 6 -C 10 )aryl, 5-10 membered heteroaryl, -(C 1 -C 4 )alkylene-(C 3 -C 6 )heterocyclyl, -(C 1 -C 4 )alkylene-(C 6 -C 10 )aryl and —(C 1 -C 4 )alkylene-(5-10 membered heteroaryl) is optionally substituted with 1, 2, 3 or 4 substituents independently selected from D, F, Cl, CN, N 3 , OH, NH 2 , (C 1 -C 6 )haloalkyl, (C 1 -C 6 )alkoxy and (C 1 -C 6 )alkylamino; and

R d is (C 3 -C 8 )cycloalkyl, wherein the (C 3 -C 8 )cycloalkyl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from D, F, Cl, OH, NH 2 , (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy and (C 1 -C 6 )alkylamino.

11. The compound according to claim 10 , wherein Q is —N(R c )C(═O)NR a R b , —N(R c )C(═O)R d , —N(R c )S(═O)NR a R b , —N(R c )S(═O) 2 NR a R b , —N(R c )S(═O) 2 R a or —C(═O)NR a R b ; and

R d is (C 3 -C 8 )cycloalkyl, wherein the (C 3 -C 8 )cycloalkyl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from D, F, Cl, OH, NH 2 , (C 1 -C 6 )alkoxy and (C 1 -C 6 )alkylamino.

12. The compound according to claim 10 , wherein Q is —N(R c )C(═O)NR a R b , —N(R c )C(═O)R d or —C(═O)NR a R b .

13. The compound according to claim 10 , wherein each of X, Y and Z is independently H, D, (C 1 -C 4 )alkyl or phenyl, wherein each of the (C 1 -C 4 )alkyl and phenyl is optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from D, F and Cl.

14. The compound according to claim 10 , wherein each of R a , R b and R c is independently H, (C 1 -C 4 )alkyl, (C 3 -C 6 )cycloalkyl, (C 3 -C 6 )heterocyclyl, -(C 1 -C 2 )alkylene-(C 3 -C 6 )cycloalkyl or -(C 1 -C 2 )alkylene-(C 3 -C 6 )heterocyclyl, wherein each of the (C 1 -C 4 )alkyl, (C 3 -C 6 )cycloalkyl, (C 3 -C 6 )heterocyclyl, (C 1 -C 2 )alkylene-(C 3 -C 6 )cycloalkyl and -(C 1 -C 2 )alkylene-(C 3 -C 6 )heterocyclyl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from D, F, Cl, CN, N 3 , OH, NH 2 , (C 1 -C 6 )haloalkyl, (C 1 -C 6 )alkoxy and (C 1 -C 6 )alkylamino.

15. The compound according to claim 10 , wherein each of X, Y and Z is independently H, D, Me, CH 2 D, CHD 2 , CD 3 , ethyl, propyl, isopropyl, phenyl or phenyl group optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from D, F and Cl.

16. The compound according to claim 10 , wherein Q is:

17. The compound of claim 1 having one of the following structures:

18. A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle or a combination thereof.

19. The pharmaceutical composition according to claim 18 further comprising a therapeutic agent selected from a chemotherapeutic agent, an anti-proliferative agent, an agent for treating atherosclerosis, an agent for treating lung fibrosis and combinations thereof.

20. The pharmaceutical composition according to claim 19 , wherein the therapeutic agent is adriamycin, rapamycin, temsirolimus, everolimus, ixabepilone, gemcitabine, cyclophosphamide, dexamethasone, etoposide, fluorouracil, afatinib, alisertib, amuvatinib, axitinib, bosutinib, brivanib, cabozantinib, cediranib, crenolanib, crizotinib, dabrafenib, dacomitinib, dasatinib, danusertib, dovitinib, erlotinib, foretinib, ganetespib, gefitinib, ibrutinib, imatinib, iniparib, lapatinib, lenvatinib, linifanib, linsitinib, masitinib, momelotinib, motesanib, neratinib, niraparib, nilotinib, oprozomib, olaparib, pazopanib, pictilisib, ponatinib, quizartinib, regorafenib, rigosertib, rucaparib, ruxolitinib, saracatinib, saridegib, sorafenib, sunitinib, tasocitinib, telatinib, tivantinib, tivozanib, tofacitinib, trametinib, vandetanib, veliparib, vemurafenib, vismodegib, volasertib, an interferon, carboplatin, topotecan, paclitaxel, vinblastine, vincristine, temozolomide, tositumomab, trabectedin, belimumab, bevacizumab, brentuximab, cetuximab, gemtuzumab, ipilimumab, ofatumumab, panitumumab, ranibizumab, rituximab, trastuzumab or a combination thereof.

21. A method of treating a proliferative disorder in a patient by administering to the patient the compound according to claim 1 wherein the proliferative disorder is metastatic cancer, colon cancer, gastric adenocarcinoma, bladder cancer, breast cancer, kidney cancer, liver cancer, lung cancer, skin cancer, thyroid cancer, cancer of the head and neck, prostate cancer, pancreatic cancer, cancer of the CNS, glioblastoma, a myeloproliferative disorder, atherosclerosis or lung fibrosis.

22. A method of treating a proliferative disorder in a patient by administering to the patient the pharmaceutical composition according to claim 18 wherein the proliferative disorder is metastatic cancer, colon cancer, gastric adenocarcinoma, bladder cancer, breast cancer, kidney cancer, liver cancer, lung cancer, skin cancer, thyroid cancer, cancer of the head and neck, prostate cancer, pancreatic cancer, cancer of the CNS, glioblastoma, a myeloproliferative disorder, atherosclerosis or lung fibrosis.